RudaCure is also actively pursuing 全球市场 entry. The company established an overseas subsidiary in 2021 and participates in major 制药/bio exhibition partnering events such as JPM, Bio-欧洲, and Bio-USA to attract overseas investment and 技术转让s. The company is also engaged with overseas accelerators including KIC (韩国创新中心), 美国 Mass Challenge program, and the 新韩Square Bridge Global Program, as well as 美国 bio events including UKC2022 and the RESI Conference. Most recently, the company won awards at IR competitions at UKC2022 (华盛顿特区) and RESI Conference (波士顿).
Regarding future plans, CEO Kim stated, "We will advance RCI001 domestic Phase 1 临床试验 within this year," adding, "Our goal is to proceed with 美国 FDA Phase 2 临床试验 by the first half of 2023."
Founded: July 2018
Main business: 新药开发 including 干眼症 and 慢性疼痛治疗药s
Achievements: Certified corporate 研发 center (2019.1), Certified 风投企业 (2019.5), Technology-innovative SME certification (2022.3), 雇佣劳动部 Strong Small Enterprise designation (2022.05). RCI001 干眼 treatment: 1 专利申请 + 2 专利s registered; RCI002 慢性疼痛治疗药: 5 专利申请s + 1 专利 registered; 2 joint development 专利s registered; 2 trademark registrations; KRW 15 billion joint 研发 agreement with 翰林制药; KRW 6 billion Series A investment completed (2022.5); RudaCure 美国A. incorporated (2021.08); Expanded to dual 松岛 HQ and 首尔 branch structure (2022.07); 2022 韩国-American Scientists Conference SBA Award; RESI Conference pitch competition award winner
📊 Related Materials & Evidence
[Patent certificate image slot]Patent Registration Certificate (RCI001)
[Event photo image slot]RESI Conference on-site
🔗 Related Links: